Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Swiss National Bank

Posted by Stanley Muller on Jul 28th, 2026

Swiss National Bank increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 38.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 157,700 shares of the biopharmaceutical company’s stock after purchasing an additional 43,700 shares during the quarter. Swiss National Bank’s holdings in Xenon Pharmaceuticals were worth $9,170,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at $32,000. Blue Trust Inc. raised its stake in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $33,000. Osaic Holdings Inc. lifted its holdings in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $65.78 on Tuesday. The stock’s 50-day moving average is $58.54 and its two-hundred day moving average is $52.87. The stock has a market cap of $6.36 billion, a PE ratio of -14.00 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting the consensus estimate of ($1.17). During the same period in the previous year, the company earned ($0.83) EPS. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on XENE shares. Wells Fargo & Company restated an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. JPMorgan Chase & Co. upped their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Royal Bank Of Canada increased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $77.20.

Get Our Latest Research Report on XENE

About Xenon Pharmaceuticals

(Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.